DDS amplifies details of marketing and disaggregation license agreement with Xethanol.
Under the terms of the previously announced agreement, DDS USA granted Xethanol an exclusive license, with certain exceptions, to market DDS USA's dry disaggregation technology to the ethanol industry in the USA. The terms called for Xethanol to earn a fee for its marketing and sales efforts, based on the sales of DDS USA's machines and for DDS not to appoint any other party to perform similar services, if Xethanol met certain minimum machine sales requirements in 2006 and 2007.
Those minimum sales requirements are ten machines in 2006 and twenty machines in 2007. Any machine orders exceeding ten in the year 2006 may be "rolled forward" and shall be applied to the required volume of thirty.
DDS also announced that as part of its recently announced Marketing and License Agreement with Xethanol, its dry disaggregation processor originally shipped to Xethanol's Hopkinton, Iowa ethanol production plant, will be shipped to DDS' new R & D facility in Norcross, Georgia, within two weeks. This machine will be dedicated to product research and DDS plans to install a second, United States built machine in its R&D facility for ongoing development of the technology.
In addition, DDS announced that its first machine shipped to Sulfur Solutions Inc. (Calgary, Canada) is expected to be assembled within two weeks.
In February 2005, DDS announced an Exclusive License Agreement between DDS Technologies USA Inc. and Sulfur Solutions, Inc. (SSI) of Calgary, Canada for the separation of impurities from Sulfur mining waste and other process residues. Subsequently, tests were conducted on an experimental DDS machine and results were extremely positive. SSI ordered a machine from DDS, which has been shipped to SSI and is expected to be assembled within two weeks.
Spencer Sterling, President & CEO of DDS USA said, "I am pleased to further amplify the details of our agreement with Xethanol and excited by the potential opportunities of our respective technologies. In addition, we are moving forward in our relationship with SSI and continue to make steady progress in the commercialization of our patented DDS technology, which we are hopeful will be a growing source of revenue."
Xethanol Corporation seeks to become a leader in the emerging biomass-to-ethanol industry. Xethanol's mission is to convert biomass that is currently being abandoned or land filled into ethanol and other valuable co-products, such as xylitol. Xethanol's strategy is to deploy proprietary bio-technologies that will extract and ferment the sugars trapped in these biomass waste concentrations. Xethanol's goal is to produce ethanol and valuable co-products more cost effectively with ethanol plants located closer to biomass sources. In Iowa, Xethanol owns and operates two ethanol production facilities, where it is deploying these technologies.
DDS holds the rights to a processing technology which maximizes the net output of a broad spectrum of organic products. The DDS System utilizes a new longitudinal micrometric separator, along with other technologies, to micronize and separate various fractions (proteins, fiber, starch, etc.) and converts processing waste streams into value added products for further processing or resale. The DDS technology is a unique process whereby fragments of organic and inorganic matter are "crushed to collision" through violent accelerations and decelerations causing the disaggregation of the structure. As part of the process, the matter is separated into the various fractions contained therein. The technology can also be applied to inorganic products. DDS Technologies USA, Inc. is a development stage company, which owns the patent for the DDS dry disaggregation system in the United States and has patents pending worldwide.
DDS Technologies USA, Inc.
|Printer friendly Cite/link Email Feedback|
|Comment:||DDS amplifies details of marketing and disaggregation license agreement with Xethanol.|
|Publication:||BIOTECH Patent News|
|Date:||Oct 1, 2005|
|Previous Article:||Bionomics granted patent for anti-cancer compounds.|
|Next Article:||CalbaTech's LifeStem files patent application for stem cell microbank.|